Business Wire

Hyperice Unveils Next Generation of Contrast Therapy Innovation, Hyperice X 2 Knee and Hyperice X 2 Shoulder

19.8.2025 15:00:00 CEST | Business Wire | Press release

Share

Driven by Athlete Feedback, the New Hyperice X 2 Unlocks a New Era of Contrast Recovery Tech With Powerful Multi-Level Compression

Hyperice, a global high-performance wellness brand, today announced the global launch of Hyperice X 2, the next generation of its best-selling Hyperice X contrast therapy line. Born from the acquisition of RecoverX in 2021 and refined through athlete testing, Hyperice X 2 is the most advanced portable contrast therapy device on the market. The Hyperice X 2 Knee and Hyperice X 2 Shoulder feature major upgrades from their predecessor devices, including deeper cold, stronger heat, and a built-in compression system to aid athletes and active users with more effective warm-up and recovery strategies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250819036830/en/

Driven by athlete feedback, the new Hyperice X 2 unlocks a new era of contrast recovery tech with powerful multi-level compression. With advanced technology tested and proven by athletes, Hyperice X 2 Knee and Hyperice X 2 Shoulder bring elite-level warm-up and recovery contrast therapy solutions in a new, user-friendly device designed for everyday use.

Hyperice X 2 marks the most substantial evolution in technology from its first-generation product. The breakthrough innovation was built and refined through a rigorous feedback loop with elite athletes. Every detail, from contrast and compression ranges to fit and portability, has been accounted for, ensuring the product meets the demands of elite athletes on the sideline alongside everyday individuals.

“Recovery and wellness are fundamental to living well, from professional athletes to people of all ages,” said Jim Huether, CEO of Hyperice. “Our mission is to provide the most advanced and effective solutions to help people move, feel, and perform better every day. With Hyperice X 2 Shoulder and Hyperice X 2 Knee, we’re not just advancing recovery, we’re redefining it. This next generation maintains the mobility and power of its predecessor while seamlessly fusing contrast therapy and compression into a sleek, more practical design.”

With advanced technology tested and proven by athletes, Hyperice X 2 Knee and Hyperice X 2 Shoulder bring elite-level warm-up and recovery contrast therapy solutions in a new, user-friendly device designed for everyday use. Whether training, rehabbing from injury or surgery, or staying active on the go, users can prime their bodies, recover faster, and perform at their best.

Key Features:

  • Addition of compression: Five levels of compression (up to 160mmHg) push temperatures deeper into the tissue, allowing users to tailor the compression to their needs and achieve a more customized fit.
  • Targeted contrast therapy: Expanded temperature ranges now span from 40°F (4°C) to 121°F (49°C), with five levels of cooling and five levels of heating, to ease inflammation and boost circulation as needed. Up from the original Hyperice X range at 45°F (7°C) to 113°F (45°C).
  • Smart control and all-in-one mobility: A new all-in-one OLED display allows seamless switching between hot, cold, and contrast therapy, as well as select compression levels. Hyperice X 2 is cord-free for use on the move, with an option to plug in to the wall for extended rehab sessions.
  • Manual and Bluetooth compatibility: New to Hyperice X 2, users can use the device with or without Bluetooth connectivity to the Hyperice app, allowing pros to leverage the technology on the sidelines easier than ever before.
  • Extended battery life: Up to 1.5 hours of continuous portable use (1 hour on max cold, 1 hour on max contrast, and 1.5 hours on max heat) - 34% more capacity compared to the original Hyperice X line.
  • Lightweight and portable: Just 2.5 lbs and TSA-friendly, Hyperice X 2 Knee and Hyperice X 2 Shoulder prioritize portability and ease of use. Each device is designed to fit both the right and left sides, to allow for increased versatility and on-the-go therapy.

From Generation 1 to Game-Changer

Building on the success of the original Hyperice X Knee and Hyperice X Shoulder models, Hyperice X 2 uses thermoelectric systems to deliver instant heat and cold temperatures on demand, without the need for ice or liquid. Hyperice X 2 introduces a clinically inspired multi-level compression system that drives temperatures deeper into tissue, ultra-convenient on-device smart controls, and cord-free portability. Now, this athlete-endorsed technology comes in a lightweight, portable device designed to help anyone, anytime, anywhere.

“I’ve put everything into this off-season to come back stronger, and recovery is where that work pays off with the Hyperice X 2 Shoulder playing a major role in my routine,” said Jayden Daniels, Washington Commanders quarterback and Hyperice athlete. “I can push my limits on the field because the built-in compression elevates my warm-up, and the contrast therapy helps me bounce back quickly for peak performance.”

Benefits of contrast therapy include:

  • Reduces swelling and pain: Contrast moves fluid, while compression limits buildup to ease inflammation and discomfort.
  • Relaxes muscles and boosts circulation: Heat loosens tight muscles, cold calms spasms, and both, paired with compression, improve blood flow.
  • Improves range of motion: Reduces stiffness, mobilizes joints, and softens tissue for smoother, safer movement.
  • Flushes waste: Contrast and compression work together to speed up the removal of lactic acid and other byproducts.
  • Aids warm-up and recovery: Increases tissue readiness before activity and helps muscles reset and recover after.

The Hyperice X 2 Knee and Hyperice X 2 Shoulder are available now in the U.S. at hyperice.com, Best Buy, Dick’s Sporting Goods, and REI for $449. In Europe and the UK, the same cutting-edge technology will be available at hyperice.com as Hyperice Contrast 2 on September 15, retailing for £399 or €449.

Assets can be found HERE.

About Hyperice

Hyperice is a technology-driven company with a giant mission, to help everyone on Earth move and live better. For more than a decade, Hyperice has led a global movement at the confluence of recovery and wellness, specializing in percussion (Hypervolt line), dynamic air compression (Normatec line), vibration (Vyper and Hypersphere lines), thermal technology (Venom line), contrast therapy (Hyperice X), and Hyperboot collaboration with Nike. Now, as a holistic high-performance wellness brand, Hyperice is designed for all - from the most elite athletes, leagues, and teams to consumers everywhere looking to unlock the best version of themselves to help them do what they love, more. Recognized as one of Fast Company’s Most Innovative Companies and a TIME Best Inventions winner, Hyperice has applied its technology and know-how to industries including fitness, hospitality, healthcare, massage, physical therapy, sports performance, and workplace wellness on a global scale. For more information, visit hyperice.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250819036830/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye